Dynavax Technologies Corporation (DVAX) News

Dynavax Technologies Corporation (DVAX): $11.40

0.03 (-0.26%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

B

Add DVAX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#31 of 346

in industry

Filter DVAX News Items

DVAX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DVAX News Highlights

  • For DVAX, its 30 day story count is now at 4.
  • Over the past 14 days, the trend for DVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • AQST, DRUG and MIRM are the most mentioned tickers in articles about DVAX.

Latest DVAX News From Around the Web

Below are the latest news stories about DYNAVAX TECHNOLOGIES CORP that investors may wish to consider to help them evaluate DVAX as an investment opportunity.

Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli

Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.

Yahoo | December 19, 2023

NextCure (NXTC) Down on Shelving Plans to Develop Candidate

NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.

Yahoo | December 15, 2023

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Yahoo | December 13, 2023

Can Dynavax Technologies (DVAX) Climb 91.59% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.6% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 5, 2023

Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How

Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.

Yahoo | November 24, 2023

Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?

Here is how Dynavax Technologies (DVAX) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.

Yahoo | November 24, 2023

Merck (MRK) to Acquire Private Neuroscience Company for $610M

Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.

Yahoo | November 22, 2023

Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m. ET.

Yahoo | November 20, 2023

Bayer (BAYRY) Stops Heart Drug Study Due to Lack of Efficacy

Bayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation.

Yahoo | November 20, 2023

SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data

SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.

Yahoo | November 17, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!